ClinicalTrials.gg
RecruitingNCT06565195PROSPECT-PDUpdated Oct 16, 2026

A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease

A Phase 1 interventional study of LY3962681 and Placebo (aCSF) in Parkinson's Disease, sponsored by Prevail Therapeutics. Recruiting at 16 sites in 5 countries. Open to participants aged 30 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Prevail Therapeutics (part of Eli Lilly and Company) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 2 months later.
Updated Oct 16, 2026Site recruiting status changed1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
30 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Parkinson Disease by Eli Lilly and Company — 2 open to participants now, 3 under way, none of them phase 3. Parkinson Disease · Eli Lilly and Company.

Planned enrollment
4th of 10
124 · median 85
Started
2024
with 1 other
Phase 1
3 of 11
2 open now
Registered
10th of 11
by date

Among the 11 studies in Parkinson Disease by Eli Lilly and Company, this one is the 4th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2024, is one of 3 in phase 1, and was the 10th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

2 of the 11 studies in Parkinson Disease by Eli Lilly and Company are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Parkinson Disease by Eli Lilly and Company, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics (PK/PD) of LY3962681 in healthy volunteers and patients with Parkinson's disease.

The study consists of two parts, the Single Ascending Dose (SAD) study and the Multiple Ascending Dose (MAD) study.

During the SAD portion of the study, healthy volunteers will receive a single dose of LY3962681 or placebo (artificial cerebrospinal fluid [aCSF]) administered intrathecally (into the spinal fluid). During the MAD portion of the study, patients with Parkinson's disease will receive two doses of either LY3962681 or placebo (aCSF) administered intrathecally (into the spinal fluid), 12 to 24 weeks apart.

  • The treatment period in the SAD study will be 1 day. The treatment period in the MAD study will be 2 dosing days, 12 to 24 weeks apart.
  • The follow-up period in the SAD study will be up to 52 weeks. The follow-up period in the MAD study will be up to 52 weeks after Dose 2.
03

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • Parkinson's disease
  • Healthy volunteers
04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is overtly healthy as determined by medical evaluation. Rescreening is allowed in this study.
  • A score greater than or equal to 24.

MAD study only

  • Stable use of background medications at least 8 weeks prior to IP administration, including but not limited to those used for treatment of Parkinson's disease (including deep brain stimulation), and the investigator must expect that participant can tolerate a minimum of 6 months without dose adjustment.
  • Participant has a diagnosis of Parkinson's disease per UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria.
  • Modified Hoehn and Yahr Stage 1 to 2.5 in the practically defined OFF state.
  • A positive result on CSF alpha-synuclein Seed Amplification Assay. (A prior positive result [within 1 year of screening] accepted with sponsor approval if patient did not participate in another Parkinson's disease clinical trial during this period.) (US and Japan only)
  • UPSIT score of 20 percentile or less, corrected for age and sex (EU and UK only).
  • An abnormal DaT-SPECT consistent with parkinsonism. (History of an abnormal DaTSPECT with the report confirmed by study investigator will be accepted.)
  • For participants not taking Parkinson's disease medications, not expected to initiate treatment within 6 months.
  • Have a body weight within 40 kg (88 pounds) to 110 kg (242 pounds), inclusive, and within the range of 17 to 34 kg/m\^2, inclusive.

Exclusion criteria

Exclusion Criteria:

  • MAD study only: Significant neurological disease affecting the central nervous system other than Parkinson's disease that may be a cause for the participant's clinical symptoms or may confound study objectives.
  • Current concomitant disease or serious or unstable illnesses, including central nervous system (SAD study only), cardiovascular, hepatic, renal, gastroenterology, respiratory, endocrinologic, neurologic (MAD study only: other than Parkinson's disease), psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the conduct of the study or that would, in the opinion of the investigator, pose an unacceptable safety risk to the participant.
  • Participant is generally frail or has any medical disorders that, in the opinion of the investigator, could interfere with study-related procedures (including safe performance of IT injection or LP), such as prohibitive spinal diseases, bleeding diathesis, coagulopathy, thrombocytopenia, or increased intracranial pressure.
  • Have a 12-lead abnormality at screening that, in the opinion of the investigator, increases the risks associated with participating in the study or may confound ECG data analysis.
  • MAD study only: Treatment with continuous intestinal delivery Parkinson's disease medication (for example, Duodopa).
  • MAD study only: Significant renal impairment (estimated [eGFR] \<45 mL/min/1.73 m\^2).

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
124 participants (estimated)

Study arms

  • Experimental
    LY3962681 (SAD)

    Single ascending dose of LY3962681 administered intrathecally (IT) to healthy volunteers.

    Drug: LY3962681

  • Placebo comparator
    Placebo (SAD)

    Single ascending dose of placebo (aCSF) administered intrathecally (IT) to healthy volunteers.

    Other: Placebo (aCSF)

  • Experimental
    LY3962681 (MAD)

    Multiple ascending doses of LY3962681 administered IT to participants with Parkinson's disease.

    Drug: LY3962681

  • Placebo comparator
    Placebo (MAD)

    Multiple ascending doses of placebo (aCSF) administered IT to participants with Parkinson's disease.

    Other: Placebo (aCSF)

Interventions

  • DrugLY3962681

    IT injection

  • OtherPlacebo (aCSF)

    IT injection

06

What researchers measure

Primary outcomes

  1. Incidence of Serious Adverse Events (SAEs)

    Time frame: Up to 76 weeks

  2. Incidence of Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to 76 weeks

  3. Number of discontinuations due to Adverse Events (AEs)

    Time frame: Up to 76 weeks

Secondary outcomes

  1. LY3962681 Maximum Observed Concentration (Cmax)

    Time frame: Up to 76 weeks

  2. LY3962681 area under the concentration versus time curve (AUC)

    Time frame: Up to 76 weeks

  3. Change from baseline in CSF total alpha-synuclein

    Time frame: Up to 76 weeks

07

Study locations

4 of 16 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Jul 2030, 70 months after the start.

Of 127 industry-sponsored phase 1 interventional studies under Parkinson Disease, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's planned 70 months is above that.

Counting every sponsor, half of 204 studies reached it within 18 months; a quarter within 5 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2024
First posted
Aug 21, 2024
StartActual
Aug 27, 2024
Primary completionEst.
Jul 23, 2030
CompletionEst.
Jul 23, 2030
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed. Quest Research Institute - Alcanza is now Recruiting
Show site
  • Institute for Neurodegenerative Disorders · New Haven, United States
Show 1 removed
  • XingImaging LLC · New Haven, United States
across 2 updates, Oct 1, 2026 – Oct 16, 2026
Site contacts
Changed at 8 sites. See the sites
Show 8 sites
  • CenExel · Englewood, United StatesContact added a•••@cenexel.com · •••5468
  • XingImaging LLC · New Haven, United StatesContact added c•••@indd.org · •••8250
  • Northwestern University Feinberg School of Medicine Dept of Neurology · Chicago, United StatesContact added c•••@northwestern.edu · •••6824
  • Quest Research Institute - Alcanza · Farmington Hills, United StatesContact added D•••@questri.com · •••8940
  • University of Pennsylvania, Dept of Neurology · Philadelphia, United StatesContact added S•••@pennmedicine.upenn.edu · •••8822
  • Universitätsklinikum Düsseldorf · Düsseldorf, GermanyContact added a•••@med.uni-duesseldorf.de · •••8262
  • Universitätsklinikum Münster · Münster, GermanyContact added i•••@ukmuenster.de · •••4427
  • Southampton General Hospital, NHS Trust · Southampton, United KingdomContact added d•••@uhs.nhs.uk · •••4989
Oct 1, 2026
Show all 2 updates
  1. Oct 16, 2026
    1 site added, 1 site removed
    Show site
    • Institute for Neurodegenerative Disorders · New Haven, United States
    Show 1 removed
    • XingImaging LLC · New Haven, United States
    + 1 other change: verification date
  2. Oct 1, 2026
    Quest Research Institute - Alcanza is now Recruiting
    Site contacts Changed at 8 sites. See the sites
    Show 8 sites
    • CenExel · Englewood, United StatesContact added a•••@cenexel.com · •••5468
    • XingImaging LLC · New Haven, United StatesContact added c•••@indd.org · •••8250
    • Northwestern University Feinberg School of Medicine Dept of Neurology · Chicago, United StatesContact added c•••@northwestern.edu · •••6824
    • Quest Research Institute - Alcanza · Farmington Hills, United StatesContact added D•••@questri.com · •••8940
    • University of Pennsylvania, Dept of Neurology · Philadelphia, United StatesContact added S•••@pennmedicine.upenn.edu · •••8822
    • Universitätsklinikum Düsseldorf · Düsseldorf, GermanyContact added a•••@med.uni-duesseldorf.de · •••8262
    • Universitätsklinikum Münster · Münster, GermanyContact added i•••@ukmuenster.de · •••4427
    • Southampton General Hospital, NHS Trust · Southampton, United KingdomContact added d•••@uhs.nhs.uk · •••4989
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06565195
Responsible party
Sponsor
First posted
Aug 21, 2024
Start date
Aug 27, 2024
Primary completion
Jul 23, 2030 (estimated)
Completion
Jul 23, 2030 (estimated)
Last update
Oct 16, 2026

Study contacts

Prevail Therapeutics
Contact
Prevail.Patients@lilly.com
917-336-9310
Travis Lewis
study director · Prevail Therapeutics, a Wholly Owned Subsidiary of Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion